同种异体血液输注对创伤性失血患者血浆外泌体miRNA表达的影响*

doi:10.3969/j.issn.1671-2587.2023.03.008

临床输血与检验 ›› 2023, Vol. 25 ›› Issue (3): 334-341.DOI: 10.3969/j.issn.1671-2587.2023.03.008

同种异体血液输注对创伤性失血患者血浆外泌体miRNA表达的影响^*

高宗帅, 张海方, 李志强

200233 上海交通大学医学院附属第六人民医院

收稿日期:2023-03-10 发布日期:2023-07-10
通讯作者: 李志强,主任医师,硕士研究生导师,主要从事血液病学诊治和输血医学研究,（E-mail）kcb039@126.com。
作者简介:高宗帅,硕士研究生在读,主要从事血型血清学与分子生物学技术研究,（E-mail）89580300@qq.com。
基金资助:
^*本课题受上海市2020年度“科技创新行动计划”生物医药科技支撑专项项目（No.20S31902900）资助

Effect of Allogeneic Blood Transfusion on Plasma Exosomal MiRNA Expression in Patients with Traumatic Blood Loss

GAO Zongshuai, ZHANG Haifang, LI Zhiqiang

Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233

Received:2023-03-10 Published:2023-07-10

摘要/Abstract

摘要： 目的通过观察异体输血对创伤性失血患者外泌体miRNA的差异表达,筛选出差异表达的外泌体miRNA,为后续靶基因和通路的研究奠定基础。方法分别采集外伤患者在输异体血前和输血后外周血标本各3例,通过对血浆标本分离收获后的外泌体miRNA高通量测序,分析比较输血前后两组外泌体miRNA差异表达情况,同时以荧光定量PCR法进一步验证差异基因表达情况。结果通过高通量测序分析,共测序到1 570个miRNA存在差异表达,实验组比较对照组,上调的有1 189个,下调的有381个,以倍数变化Fold change≥2.0,P-value ≤0.05作为差异miRNA筛选的阈值,筛选出显著变化的差异表达miRNA有14个,其中显著上调的miRNA有5个,分别为miR-499a-5p、miR-200a-3p、miR-372-3p、miR-novel-chr12_5583、miR-novel-chr22_24253;显著下调的miRNA有9个,分别为miR-6852-5p、miR-452-5p、miR-1287-5p、miR-204-3p、miR-375-3p、miR-502-3p、miR-345-5p、miR-novel-chr7_38986、miR-451a。结论输注同种异体血液对创伤性失血患者的外泌体miRNA存在差异表达。其发生机制可能通过不同信号通路对患者机体免疫系统调节产生影响。然而,对患者机体免疫调节程度、与肿瘤的相关性有待于扩大样本量进一步研究。

关键词: 输血, 外泌体, miRNA, 高通量测序

Abstract: Objective To observe the differential expression of exosomal miRNAs in patients with traumatic blood loss induced by allogeneic blood transfusion, screen out the differentially expressed exosomal miRNAs, and lay the foundation for the subsequent study of target genes and pathways. Methods Peripheral blood samples were collected from 3 trauma patients before and after transfusion, respectively. Through high-throughput sequencing of exosome miRNA extracted and harvested from plasma samples, the differential expression of exosome miRNA was analyzed and compared between the two groups. Meanwhile, fluorescence quantitative PCR was used to further verify the differential gene expression. Results High-throughput sequencing analysis found that a total of 1 570 miRNA were differentially expressed. Compared with the control group, 1 189 miRNA were up-regulated and 381 miRNA were down-regulated in the experimental group. When fold change≥2.0, P-value ≤0.05 were used as the threshold for differential miRNA screening, there were 14 differentially expressed miRNA with significant changes. 5 miRNA were significantly up-regulated, including miR-499a-5p, miR-200a-3p, miR-372-3p, miR-novel-chr12_5583 and miR-novel-chr22_24253. 9 miRNA were significantly down-regulated, including miR-6852-5p, miR-452-5p, miR-1287-5p, miR-204-3p, miR-375-3p, miR-502-3p, miR-345-5p, miR-novel-chr7_38986 and miR-451a. Conclusions Allogeneic blood transfusion triggers differential expression of exosomal miRNA in patients with traumatic blood loss. Its mechanism may affect the regulation of the patient's immune system through different signaling pathways. However, the degree of immune regulation in patients and the correlation with tumors need to be further studied with larger sample size.

Key words: Blood transfusion, Exosome, miRNA, High-throughput sequencing

中图分类号:

R457

高宗帅, 张海方, 李志强. 同种异体血液输注对创伤性失血患者血浆外泌体miRNA表达的影响^*[J]. 临床输血与检验, 2023, 25(3): 334-341.

GAO Zongshuai, ZHANG Haifang, LI Zhiqiang. Effect of Allogeneic Blood Transfusion on Plasma Exosomal MiRNA Expression in Patients with Traumatic Blood Loss[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(3): 334-341.

参考文献

[1] JAN A T,RAHMAN S,KHAN S,et al.Biology,pathophys
iological role,and clinical implications of exosomes:a critical appraisal[J].Cells,2019,8(2):99.
[2] QING L M,CHEN H W,TANG J Y,et al.Exosomes and their microRNA cargo:new players in peripheral nerve regeneration[J].Neurorehabil Neural Repair,2018,32(9):765-776.
[3] MATHIEU M,MARTIN-JAULAR L,LAVIEU G,et al.Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication[J].Nat Cell Biol,2019,21(1):9-17.
[4] REMY K E,HALL M W,CHOLETTE J,et al.Mechanisms of red blood cell transfusion-related immunomodulation[J].Transfusion,2018,58(3):804-815.
[5] PEGTEL D M,GOULD S J.Exosomes[J].Annu Rev Biochem,2019,88:487-514.
[6] OUYANG L,LIU R D,LEI D Q,et al.miR-499a-5p promotes 5-FU resistance and the cell proliferation and migration through activating PI3K/Akt signaling by targeting PTEN in pancreatic cancer[J].Ann Transl Med,2021,9(24):1798.
[7] WAN P,CHEN Z L,HUANG M Z,et al.miR-200a-3p facilitates bladder cancer cell proliferation by targeting the A20 gene[J].Transl Androl Urol,2021,10(11):4262-4274.
[8] FAN G H,ZHANG C Z,WEI X Y,et al.NEAT1/hsa-miR-372-3p axis participates in rapamycin-induced lipid metabolic disorder[J].Free Radic Biol Med,2021,167:1-11.
[9] TAN Y E,XING Y,RAN B L,et al.LINC01235-TWIST2 feedback loop facilitates epithelial-mesenchymal transition in gastric cancer by inhibiting THBS2[J].Aging,2020,12(24):25060-25075.
[10] LIN X,HAN L,GU C C,et al.miR-452-5p promotes colorectal cancer progression by regulating an ERK/MAPK positive feedback loop[J].Aging,2021,13(5):7608-7626.
[11] HAO W W,ZHU Y P,GUO Y,et al.miR-1287-5p upregulation inhibits the EMT and pro-inflammatory cytokines in LPS-induced human nasal epithelial cells (HNECs)[J].Transpl Immunol,2021,68:101429.
[12] ZHANG L Y,ZHU Z Y,ZHANG Q,et al.The upregulation of miR-204-3p in LPS-induced acute lung injury aggravated pulmonary endothelial cells apoptosis via targeting sulfatase 2[J].Acta Biochim Pol,2021,68(2):217-222.
[13] CHENG S H,DI Z H,HIRMAN A R,et al.miR-375-3p alleviates the severity of inflammation through targeting YAP1/LEKTI pathway in HaCaT cells[J].Biosci Biotechnol Biochem,2020,84(10):2005-2013.
[14] LIU F,DONG Z,LIN Y F,et al.microRNA-502-3p promotes Mycobacteriumtuberculosis survival in macrophages by modulating the inflammatory response by targeting ROCK1[J].Mol Med Rep,2021,24(5):753.
[15] ZHAO M,WANG K J,SHANG J B,et al.miR-345-5p inhibits tumorigenesis of papillary thyroid carcinoma by targeting SETD7[J].Aoms,2020,16(4):888-897.
[16] SHEN Y Y,CUI J Y,YUAN J,et al.miR-451a suppressed cell migration and invasion in non-small cell lung cancer through targeting ATF2[J].Eur Rev Med Pharmacol Sci,2018,22(17):5554-5561.
[17] LIU Y,YANG H Z,JIANG Y J,et al.miR-451a is downregulated and targets PSMB8 in prostate cancer[J].The Kaohsiung J Med Scie,2020,36(7):494-500.
[18] MANASA V G,THOMAS S,KANNAN S.miR-144/451a cluster synergistically modulates growth and metastasis of Oral Carcinoma[J].Oral Dis,2023,29(2):584-594.
[19] ZHANG H,CHEN P,YANG J.miR-451a suppresses the development of breast cancer via targeted inhibition of CCND2[J].Mol Cell Probes,2020,54:101651.
[20] FU W,YU G C,LIANG J N,et al.miR-144-5p and miR-451a inhibit the growth of cholangiocarcinoma cells through decreasing the expression of ST8SIA4[J].Front Oncol,2021,10:563486.
[21] WANG Q,SHANG J,ZHANG Y,et al.miR-451a restrains the growth and metastatic phenotypes of papillary thyroid carcinoma cells via inhibiting ZEB1[J].Biomed Pharmacother,2020,127:109901.
[22] XIA S F,HUANG J Q,YAN L J,et al.miR-150 promotes progressive T cell differentiation via inhibiting FOXP1 and RC3H1[J].Hum Immunol,2022,83(11):778-788.
[23] JIANG M,ZHANG J,QIAN L L,et al.MOZ forms an autoregulatory feedback loop with miR-223 in AML and monocyte/macrophage development[J].iScience,2019,11:189-204.
[24] ZHANG J,JIANG M,QIAN L L,et al.The STAT3-miR-223-TGFBR3/HMGCS1 axis modulates the progression of cervical carcinoma[J].Mol Oncol,2020,14(9):2313-2331.
[25] SHEEDY F J.Turning 21:induction of miR-21 as a key switch in the inflammatory response[J].Front Immunol,2015,6:19.
[26] SANG W,WANG Y,ZHANG C,et al.miR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway[J].Immunol Lett,2016,172:1-10.
[27] OLIVIERI F,PRATTICHIZZO F,GIULIANI A,et al.miR-21 and miR-146a:the microRNAs of inflammaging and age-related diseases[J].Ageing Res Rev,2021,70:101374.
[28] FEI Y R,CHAULAGAIN A,WANG T Y,et al.miR-146a down-regulates inflammatory response by targeting TLR3 and TRAF6 in Coxsackievirus B infection[J].RNA,2020,26(1):91-100.
[29] DANESH A,INGLIS H C,JACKMAN R P,et al.Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines,boosting T-cell responses in vitro[J].Blood,2014,123(5):687-696.
[30] HUANG H B,ZHU J F,FAN L P,et al.microRNA profiling of exosomes derived from red blood cell units:implications in transfusion-related immunomodulation[J].BioMed Res Int,2019,2019:1-10.

同种异体血液输注对创伤性失血患者血浆外泌体miRNA表达的影响^*

Effect of Allogeneic Blood Transfusion on Plasma Exosomal MiRNA Expression in Patients with Traumatic Blood Loss

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	赵立哲, 李剑平, 李晓丰. 肠道菌群与人类ABO血型^*[J]. 临床输血与检验, 2023, 25(3): 297-301.
[2]	陈怡静, 卓海龙, 张怡, 程晨, 骆群. X射线辐照对淋巴细胞的灭活能力及对悬浮红细胞质量的影响研究[J]. 临床输血与检验, 2023, 25(3): 320-323.
[3]	黎欢, 谢佳, 何洪伟, 彭涛, 张利, 谭强, 胡燕, 吴玲. 心脏外科围术期大量输血患者输血相关呼吸系统不良反应回顾性调查[J]. 临床输血与检验, 2023, 25(3): 358-362.
[4]	李正峰, 王佳, 陈萍, 甘珊, 李好, 段灵, 陈鑫, 杨柳春, 王阳, 胡红兵. 儿科住院拟输血患者意外抗体阳性结果分布及影响因素横断面研究[J]. 临床输血与检验, 2023, 25(3): 374-378.
[5]	施艺璇, 何苏英, 彭永正. 电子匹配信息系统辅助的Rh血型五抗原配合性输注的安全性和有效性研究[J]. 临床输血与检验, 2023, 25(3): 379-383.
[6]	贺敏威, 詹林盛. 2022年度输血医学科研新进展^*[J]. 临床输血与检验, 2023, 25(3): 415-419.
[7]	中国输血协会免疫血液学专业委员会. 输血依赖型地中海贫血（TDT）患者临床输血中国专家共识[J]. 临床输血与检验, 2023, 25(2): 163-169.
[8]	黄蓉, 张宁洁, 郝珂, 郭天虹, 黄雪原, 谷兰, 傅云峰, 黄远帅, 王勇军, 陈秉宇, 周岚, 桂嵘. 从《AABB技术手册》（18版-20版）看国际输血技术新走向^*[J]. 临床输血与检验, 2023, 25(2): 170-179.
[9]	邓桂花, 龙馨妍, 孙亚纯, 王雷萍, 张传国, 孟庆宝. 智慧型输血医学科的建设[J]. 临床输血与检验, 2023, 25(2): 185-189.
[10]	樊凤艳, 马越云. RhD血型不匹配异基因造血干细胞移植输血RhD血型选择[J]. 临床输血与检验, 2023, 25(2): 189-192.
[11]	王瑞含, 彭娟, 刘浩, 刘久波. 回收式自体输血对高危剖宫产妇凝血功能及血液中胎儿成分的影响^*[J]. 临床输血与检验, 2023, 25(2): 215-219.
[12]	葛霜, 汪德清. 2021—2022年度输血医学研究进展^*[J]. 临床输血与检验, 2023, 25(2): 276-281.
[13]	谢东甫, 黄霞, 杨俊鸿, 孙洁, 张晰, 何涛. 国内外血液安全监测报告若干数据指标的比较与分析^*[J]. 临床输血与检验, 2023, 25(1): 16-20.
[14]	王胜蓝, 贵明飞, 华敏玉, 李鹏, 卓创近, 刘钟梅, 杨霞, 黄霞, 何涛. 急性输血不良反应发生时间调查及分析^*[J]. 临床输血与检验, 2023, 25(1): 33-37.
[15]	周姗姗, 荆亚楠, 侯晓燕, 薛亚飞, 张媛媛, 黄霞, 王敏. 某三甲医院2021~2022年276例输血不良反应回顾性分析^*[J]. 临床输血与检验, 2023, 25(1): 38-43.